Related Experiment Video
Updated: Jul 13, 2026
06:37
Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
Published on: October 20, 2010
Sentinel node localization in breast cancer patients using intradermal dye injection
Acta Oncologica (Stockholm, Sweden)
|September 15, 2000
Summary
Patent Blue dye effectively identifies sentinel nodes (SNs) in breast cancer surgery, improving localization rates after procedural changes. Further analysis revealed metastasis in 43% of SNs, highlighting the importance of detailed pathological examination.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel node biopsy is crucial for breast cancer staging.
- Accurate sentinel node identification impacts treatment decisions.
Purpose of the Study:
- To evaluate the efficacy of Patent Blue dye for sentinel node localization in breast cancer surgery.
- To assess the learning curve associated with sentinel node dissection for surgeons.
Main Methods:
- Intradermal injection of Patent Blue dye in 161 breast cancer operations.
- Analysis of surgical and pathological identification of blue lymph nodes.
- Evaluation of localization rates before and after a procedural modification.
- Assessment of metastasis detection rates and false-negative rates.
Main Results:
- Initial surgical localization rate was 60%, increasing to 83% after procedural changes.
- Pathologist identification increased the overall localization rate to 70%.
- Metastasis was detected in 43% of sentinel nodes.
- Step-sectioning and immunohistochemistry identified additional metastases in 36% of positive cases.
- The false-negative rate for sentinel nodes was 9.1%.
Conclusions:
- Patent Blue dye is a viable method for sentinel node localization in breast cancer.
- Surgical technique modifications and surgeon experience significantly improve localization rates.
- Comprehensive pathological examination, including immunohistochemistry, is essential for accurate metastasis detection.
